報價延遲最少15分鐘:2025/05/13 22:53 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.52 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.07/-0.64
|
|
企業價值
129.99M
|
| 資產負債 |
|
每股賬面淨值
1.53
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/13 22:53 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Vigil Neuroscience Inc is a clinical-stage biotechnology company engaged in improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. Microglia are the sentinel immune cells of the brain and play a critical role in maintaining central nervous system (CNS) health and responding to damage caused by disease. The group provides solutions for fully human monoclonal antibody and Oral small molecule TERM2 agonist. |